Baudax Bio, Inc. (BXRX): Price and Financial Metrics

Baudax Bio, Inc. (BXRX): $0.14

0.02 (+13.16%)

POWR Rating

Component Grades













Add BXRX to Watchlist
Sign Up

Industry: Biotech



in industry

BXRX Stock Summary

  • BXRX has a higher market value than only 0.13% of US stocks; more precisely, its current market capitalization is $2,460,461.
  • BXRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 97.94% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BXRX comes in at -761.16% -- higher than that of only 0.69% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BAUDAX BIO INC are GMBL, REED, AEL, EMCF, and SIEB.
  • BXRX's SEC filings can be seen here. And to visit BAUDAX BIO INC's official web site, go to

BXRX Valuation Summary

  • In comparison to the median Healthcare stock, BXRX's price/earnings ratio is 100.43% lower, now standing at -0.1.
  • BXRX's EV/EBIT ratio has moved up 0.6 over the prior 37 months.

Below are key valuation metrics over time for BXRX.

Stock Date P/S P/B P/E EV/EBIT
BXRX 2022-11-25 2.1 -0.1 -0.1 -0.3
BXRX 2022-11-23 2.2 -0.2 -0.1 -0.3
BXRX 2022-11-22 2.1 -0.1 -0.1 -0.3
BXRX 2022-11-21 2.1 -0.1 -0.1 -0.3
BXRX 2022-11-18 2.0 -0.1 -0.1 -0.3
BXRX 2022-11-17 2.1 -0.1 -0.1 -0.3

BXRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BXRX has a Quality Grade of F, ranking ahead of 1.16% of graded US stocks.
  • BXRX's asset turnover comes in at 0.011 -- ranking 79th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows BXRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.011 -2.189 -5.026
2021-06-30 0.008 -3.584 -4.211
2021-03-31 0.010 -2.695 -14.661
2020-12-31 0.007 -2.513 28.623
2020-09-30 0.006 -1.854 20.273
2020-06-30 0.006 -0.862 40.097

BXRX Price Target

For more insight on analysts targets of BXRX, see our BXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.00 Average Broker Recommendation 1.25 (Strong Buy)

BXRX Stock Price Chart Interactive Chart >

Price chart for BXRX

BXRX Price/Volume Stats

Current price $0.14 52-week high $14.52
Prev. close $0.12 52-week low $0.12
Day low $0.12 Volume 1,915,300
Day high $0.15 Avg. volume 781,949
50-day MA $0.20 Dividend yield N/A
200-day MA $1.01 Market Cap 2.79M

Baudax Bio, Inc. (BXRX) Company Bio

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

BXRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BXRX Latest Social Stream

Loading social stream, please wait...

View Full BXRX Social Stream

Latest BXRX News From Around the Web

Below are the latest news stories about BAUDAX BIO INC that investors may wish to consider to help them evaluate BXRX as an investment opportunity.

Noble Financial Reaffirms Their Buy Rating on Baudax Bio (BXRX)

In a report released today, Gregory Aurand from Noble Financial maintained a Buy rating on Baudax Bio (BXRX - Research Report), with a price target of $0.60. The company's shares closed yesterday at $0.14.Aurand covers the Healthcare sector, focusing on stocks such as Baudax Bio, ChitogenX, and BioSig Technologies. According to TipRanks, Aurand has an average return of -60.9% and a 17.65% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baudax Bio with a $0.60 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $18.86 and a one-year low of $0.13.

Ryan Adist on TipRanks | November 10, 2022

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

BX 1000 Phase II Trial Underway BX 2000 Dose Escalation Study Progressing ANJESO® Vials Sold to End Users Up 16% Third Quarter Year-Over-Year USPTO Issues Note of Allowance for additional Orange Book Listable ANJESO® Patent MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the three and nine months ended September 30, 2022,

Yahoo | November 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back and get ready for another week of trading as we break down the biggest pre-market stock movers for Monday morning!

William White on InvestorPlace | October 31, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | October 4, 2022

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Baudax Bio (BXRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report) and Baudax Bio (BXRX – Research Report). Regeneron (REGN) J.P. Morgan analyst Chris Schott maintained a Hold rating on Regeneron on September 19 and set a price target of $725.00. The company's shares closed last Tuesday at $704.22. According to TipRanks.

Howard Kim on TipRanks | September 21, 2022

Read More 'BXRX' Stories Here

BXRX Price Returns

1-mo -31.47%
3-mo -58.82%
6-mo -81.82%
1-year -98.94%
3-year -99.93%
5-year N/A
YTD -98.18%
2021 -78.30%
2020 -85.40%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8415 seconds.